The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers
Open accessAbstract
Myc is one of the most commonly deregulated oncogenes in human cancer, yet therapies directly targeting Myc hyperactivation are not presently available in the clinic. The evolutionarily conserved function of Myc in modulating protein synthesis control is critical to the Myc oncogenic program. Indeed, enhancing the protein synthesis capacity of cancer cells directly contributes to their survival, proliferation, and genome instability. Therefore, inhibiting enhanced protein synthesis may represent a highly relevant strategy for the treatment of Myc-dependent human cancers. However, components of the translation machinery that can be exploited as therapeutic targets for Myc-driven cancers remain poorly defined. Here, we uncover a surprising and important functional link between Myc and mammalian target of rapamycin (mTOR)-dependent phosphorylation of eukaryotic translation initiation factor 4E binding protein-1 (4EBP1), a master regulator of protein synthesis control. Using a pharmacogenetic approach, we find that mTOR-dependent phosphorylation of 4EBP1 is required for cancer cell survival in Myc-dependent tumor initiation and maintenance. We further show that a clinical mTOR active site inhibitor, which is capable of blocking mTOR-dependent 4EBP1 phosphorylation, has remarkable therapeutic efficacy in Myc-driven hematological cancers. Additionally, we demonstrate the clinical implications of these results by delineating a significant link between Myc and mTOR-dependent phosphorylation of 4EBP1 and therapeutic response in human lymphomas. Together, these findings reveal that an important mTOR substrate is found hyperactivated downstream of Myc oncogenic activity to promote tumor survival and confers synthetic lethality, thereby revealing a unique therapeutic approach to render Myc druggable in the clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · cited 1×
“Another master regulator of protein synthesis frequently found deregulated in cancer is the mammalian target of rapamycin (mTOR) kinase (14, 15).”
Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets
Sonenberg, N., & Hinnebusch, A. G. (2009) · Cell · doi:10.1016/j.cell.2009.01.042 · Cited by 3,304
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Regulation of translation initiation by FRAP/mTOR
Gingras, A.-C., Raught, B., & Sonenberg, N. (2001) · Genes & Development · doi:10.1101/gad.887201 · Cited by 1,545
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313 · cited 3×
“4 nM inhibition constant), was administered based on previously published pharmacokinetic data that demonstrated 1 mg/kg daily dosing achieved maximal mTOR inhibition while minimizing off-target effects (27).”
Self-citationDang, C. V., O’Donnell, K. A., Zeller, K. I., Nguyen, T., Osthus, R. C., & Li, F. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.014 · Cited by 1,188 · cited 1×
“T Myc transcription factor is one of the most frequently activated oncogenes in human tumors (1).”
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,082
Self-citationJohnson, N. A., Slack, G. W., Savage, K. J., Connors, J. M., Ben-Neriah, S., Rogic, S., Scott, D. W., Tan, K. L., Steidl, C., Sehn, L. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0985 · Cited by 975
MYC as a regulator of ribosome biogenesis and protein synthesis
van Riggelen, J., Yetil, A., & Felsher, D. W. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2819 · Cited by 956
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951
NAVÉ, B. T., Ouwens, D. M., Withers, D. J., Alessi, D. R., & Shepherd, P. R. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3440427 · Cited by 932
Gingras, A.-C., Kennedy, S. G., O'Leary, M. A., Sonenberg, N., & Hay, N. (1998) · Genes & Development · doi:10.1101/gad.12.4.502 · Cited by 886
Choo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P., & Blenis, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809136105 · Cited by 810
Oncogenic PI3K deregulates transcription and translation
Bader, A. G., Kang, S., Zhao, L., & Vogt, P. K. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1753 · Cited by 798
Ribosomal protein S6 phosphorylation: from protein synthesis to cell size
Ruvinsky, I., & Meyuhas, O. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.04.003 · Cited by 779
The mTOR pathway in the control of protein synthesis
Wang, X., & Proud, C. G. (2006) · Physiology · doi:10.1152/physiol.00024.2006 · Cited by 778
Hochedlinger, K., Yamada, Y., Beard, C., & Jaenisch, R. (2005) · Cell · doi:10.1016/j.cell.2005.02.018 · Cited by 747
Control of p70 S6 kinase by kinase activity of FRAP in vivo
Brown, E. J., Beal, P. A., Keith, C. T., Chen, J., Bum Shin, T., & Schreiber, S. L. (1995) · Nature · doi:10.1038/377441a0 · Cited by 705
Impairment of T-cell-dependent B-cell responses and B-l cell development in CD19-deficient mice
Rickert, R. C., Rajewsky, K., & Roes, J. (1995) · Nature · doi:10.1038/376352a0 · Cited by 664
Savage, K. J., Johnson, N. A., Ben-Neriah, S., Connors, J. M., Sehn, L. H., Farinha, P., Horsman, D. E., & Gascoyne, R. D. (2009) · Blood · doi:10.1182/blood-2009-05-220095 · Cited by 660
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis
Ruggero, D., Montanaro, L., Ma, L., Xu, W., Londei, P., Cordon-Cardo, C., & Pandolfi, P. P. (2004) · Nature Medicine · doi:10.1038/nm1042 · Cited by 586
Self-citationBarrans, S., Crouch, S., Smith, A., Turner, K., Owen, R., Patmore, R., Roman, E., & Jack, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3947 · Cited by 552
Hsieh, A. C., Costa, M., Zollo, O., Davis, C., Feldman, M. E., Testa, J. R., Meyuhas, O., Shokat, K. M., & Ruggero, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.021 · Cited by 434
Self-citationSuppression of Myc oncogenic activity by ribosomal protein haploinsufficiency
Barna, M., Pusic, A., Zollo, O., Costa, M., Kondrashov, N., Rego, E., Rao, P. H., & Ruggero, D. (2008) · Nature · doi:10.1038/nature07449 · Cited by 424
Self-citationChesi, M., Robbiani, D. F., Sebag, M., Chng, W. J., Affer, M., Tiedemann, R., Valdez, R., Palmer, S. E., Haas, S. S., Stewart, A. K., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.007 · Cited by 393
Graff, J. R., Konicek, B. W., Vincent, T. M., Lynch, R. L., Monteith, D., Weir, S. N., Schwier, P., Capen, A., Goode, R. L., Dowless, M. S., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32044 · Cited by 380
Shou, Y., Martelli, M. L., Gabrea, A., Qi, Y., Brents, L. A., Roschke, A., Dewald, G., Kirsch, I. R., Bergsagel, P. L., & Kuehl, W. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.1.228 · Cited by 347
Chng, W.-J., Huang, G. F., Chung, T. H., Ng, S. B., Gonzalez-Paz, N., Troska-Price, T., Mulligan, G., Chesi, M., Bergsagel, P. L., & Fonseca, R. (2011) · Leukemia · doi:10.1038/leu.2011.53 · Cited by 270
Kanungo, A., Medeiros, L. J., Abruzzo, L. V., & Lin, P. (2006) · Modern Pathology · doi:10.1038/modpathol.3800500 · Cited by 208
Mothe‐Satney, I., Yang, D., Fadden, P., Haystead, T., & Lawrence, J. C. (2000) · Molecular and Cellular Biology · doi:10.1128/.20.10.3558-3567.2000 · Cited by 187
The Role of Myc-Induced Protein Synthesis in Cancer
Ruggero, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1970 · Cited by 186 · cited 1×
“One of the major and immediate downstream effects of Myc activation is a dramatic increase in the protein synthetic capacity of the cell that results in increased cell survival, proliferation, and genome instability (7 – 9).”
Self-citationMYC regulation of a “poor-prognosis” metastatic cancer cell state
Wolfer, A., Wittner, B. S., Irimia, D., Flavin, R. J., Lupien, M., Gunawardane, R. N., Meyer, C. A., Lightcap, E. S., Tamayo, P., Mesirov, J. P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914203107 · Cited by 177
Prochownik, E. V., & Vogt, P. K. (2010) · Genes & Cancer · doi:10.1177/1947601910377494 · Cited by 170
Crosstalk between c‐Myc and ribosome in ribosomal biogenesis and cancer
Dai, M., & Lu, H. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21895 · Cited by 167
The role of c-myc in regulation of translation initiation
Schmidt, E. V. (2004) · Oncogene · doi:10.1038/sj.onc.1207548 · Cited by 166 · cited 1×
“For example, Myc is known to transcriptionally activate the eIF4E oncogene (39), a finding we validated at the protein level in human DLBCL (Fig.”
Tumor suppression by small molecule inhibitors of translation initiation
Chen, L., Aktas, B. H., Wang, Y., He, X., Sahoo, R., Zhang, N., Denoyelle, S., Kabha, E., Yang, H., Yefidoff‐Freedman, R., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.598 · Cited by 104
Targeting Synthetic Lethal Interactions between Myc and the eIF4F Complex Impedes Tumorigenesis
Lin, C., Nasr, Z., Premsrirut, P. K., Porco, J. A. J., Hippo, Y., Lowe, S. W., & Pelletier, J. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.02.010 · Cited by 94
Wall, M., Poortinga, G., Stanley, K. L., Lindemann, R. K., Bots, M., Chan, C. J., Bywater, M. J., Kinross, K. M., Astle, M. V., Waldeck, K., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0404 · Cited by 64
Sato, H., Minei, S., Hachiya, T., Yoshida, T., & Takimoto, Y. (2006) · International Journal of Urology · doi:10.1111/j.1442-2042.2006.01399.x · Cited by 49
Modulation of 4E-BP1 Function as a Critical Determinant of Enzastaurin-Induced Apoptosis
Dumstorf, C. A., Konicek, B. W., McNulty, A. M., Parsons, S. H., Furic, L., Sonenberg, N., & Graff, J. R. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0413 · Cited by 32
Cited by
The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism
Hoxhaj, G., & Manning, B. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0216-7 · Cited by 2,137
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L., & Dang, C. V. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0507 · Cited by 1,375
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion
Dhanasekaran, R., Deutzmann, A., Mahauad-Fernandez, W. D., Hansen, A. S., Gouw, A. M., & Felsher, D. W. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00549-2 · Cited by 986
Regulation and metabolic functions of mTORC1 and mTORC2
Szwed, A., Kim, E., & Jacinto, E. (2021) · Physiological Reviews · doi:10.1152/physrev.00026.2020 · Cited by 813
Metadata
- Authors
- Pourdehnad, M., Truitt, M. L., Siddiqi, I. N., Ducker, G. S., Shokat, K. M., & Ruggero, D.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2013-06-26
- Volume
- 110
- Issue
- 29
- Pages
- 11988-11993
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2151748280
- Cited by
- 286
- References
- 42
- FWCI
- 11.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.